Baidu
map

Br J Cancer:儿童、青少年和年轻成年男性癌症幸存者的生殖与婚姻研究

2016-05-31 Mechront 译 MedSci原创

随着年轻的癌症患者的生存期增加,让长期随访研究的效度变得重要。在这个国家的队列研究中,我们探讨了年轻时代的癌症对男性幸存者生殖和婚姻状况的影响。研究纳入了1965-1985年间挪威相关数据库的年轻癌症患者,与非癌症男性相比,探究年轻男性癌症幸存者的生殖和婚姻状况。数据显示,男性癌症幸存者 (n=2687)亲子鉴定更少((HR: 0.72, 95% CI: 0.68–0.76)。15岁前确诊的癌症常

随着年轻的癌症患者的生存期增加,让长期随访研究的效度变得重要。在这个国家的队列研究中,我们探讨了年轻时代的癌症对男性幸存者生殖和婚姻状况的影响。

研究纳入了1965-1985年间挪威相关数据库的年轻癌症患者,与非癌症男性相比,探究年轻男性癌症幸存者的生殖和婚姻状况。

数据显示,男性癌症幸存者 (n=2687)亲子鉴定更少((HR: 0.72, 95% CI: 0.68–0.76)。15岁前确诊的癌症常为睾丸癌、脑肿瘤、淋巴瘤、白血病和骨肿瘤。男性肿瘤幸存者更可能接受辅助生殖(RR: 3.32, 95% CI: 2.68–4.11)。第一胎出现围产儿死亡、先天性畸形、小于胎龄儿、低出生体重儿或早产的风险无差异。男性癌症幸存者不太可能结婚(HR: 0.93, 95% CI: 0.86–1.00),特别是脑肿瘤幸存者。

在这个国家的队列研究中,我们证明了男性癌症幸存者有更少的亲子鉴定和更多的使用辅助生殖,但对他们的第一代后代没有不利影响。

原始出处:

Gunnes MW, et al. Reproduction and marriage among male survivors of cancer in childhood, adolescence and young adulthood: a national cohort study.Br J Cancer. 2016;doi:10.1038/bjc.2015.455.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1438767, encodeId=03391438e67e4, content=<a href='/topic/show?id=5e61e13494d' target=_blank style='color:#2F92EE;'>#癌症幸存者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71349, encryptionId=5e61e13494d, topicName=癌症幸存者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jun 02 13:11:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88053, encodeId=8b2d8805342, content=确实如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Wed Jun 01 15:36:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87978, encodeId=8a188e9788f, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 01 07:33:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87946, encodeId=745d8e94643, content=需进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:41:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87945, encodeId=36848e9450d, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:40:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1438767, encodeId=03391438e67e4, content=<a href='/topic/show?id=5e61e13494d' target=_blank style='color:#2F92EE;'>#癌症幸存者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71349, encryptionId=5e61e13494d, topicName=癌症幸存者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jun 02 13:11:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88053, encodeId=8b2d8805342, content=确实如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Wed Jun 01 15:36:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87978, encodeId=8a188e9788f, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 01 07:33:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87946, encodeId=745d8e94643, content=需进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:41:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87945, encodeId=36848e9450d, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:40:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-06-01 沉心多思

    确实如此

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1438767, encodeId=03391438e67e4, content=<a href='/topic/show?id=5e61e13494d' target=_blank style='color:#2F92EE;'>#癌症幸存者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71349, encryptionId=5e61e13494d, topicName=癌症幸存者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jun 02 13:11:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88053, encodeId=8b2d8805342, content=确实如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Wed Jun 01 15:36:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87978, encodeId=8a188e9788f, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 01 07:33:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87946, encodeId=745d8e94643, content=需进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:41:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87945, encodeId=36848e9450d, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:40:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-06-01 1dd8c52fm63(暂无匿称)

    学习一下!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1438767, encodeId=03391438e67e4, content=<a href='/topic/show?id=5e61e13494d' target=_blank style='color:#2F92EE;'>#癌症幸存者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71349, encryptionId=5e61e13494d, topicName=癌症幸存者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jun 02 13:11:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88053, encodeId=8b2d8805342, content=确实如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Wed Jun 01 15:36:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87978, encodeId=8a188e9788f, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 01 07:33:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87946, encodeId=745d8e94643, content=需进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:41:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87945, encodeId=36848e9450d, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:40:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-06-01 milkshark

    需进一步研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1438767, encodeId=03391438e67e4, content=<a href='/topic/show?id=5e61e13494d' target=_blank style='color:#2F92EE;'>#癌症幸存者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71349, encryptionId=5e61e13494d, topicName=癌症幸存者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jun 02 13:11:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88053, encodeId=8b2d8805342, content=确实如此, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Wed Jun 01 15:36:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87978, encodeId=8a188e9788f, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 01 07:33:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87946, encodeId=745d8e94643, content=需进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:41:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87945, encodeId=36848e9450d, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:40:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-06-01 milkshark

    的确这样

    0

相关资讯

Nature、Cell聚焦:癌症免疫疗法“全新综述”TOP8(附4项突破进展……)

近几年,癌症免疫疗法进入飞速发展阶段,然而尽管这一突破性的技术给科学界带来了很大惊喜,也吸引了一大批制药企业加入这一领域,但包括检查点抑制剂、过继细胞疗法、癌症疫苗在内的各项技术仍存在很多需要克服的障碍。

美政府研究表明:手机辐射与癌症之间存在联系

由美国FDA资助的国家毒理学计划(National Toxicology Program,NTP)研究团队发现,暴露在手机辐射下的雄性小鼠患罕见脑癌和心脏癌症的风险增加。这项研究成果以预印本文献的形式发表在冷泉港实验室(CSHL)主办的BioRxiv上(1)。 据了解,这项研究成果一经公布就在美国社会引起轩然大波,人们又开始重新审视无处不在的电子设备对人体的危害。 实际上(不好意思,又出现了

牛津大学的这家创业公司,居然要『逆转』癌症干细胞

这个月,可能大家都被一笔2440万美元的融资刷过屏,这笔融资的获益者是一家名叫Oxstem的公司,这家公司由牛津大学孵化。对于一家生物公司来说,2000多万虽不是什么了不得的数字,但也是创下了英国学术机构科技初创公司融资的新纪录。 这是一家成立于2013年的年轻公司,之所以能获得投资人的青睐,与它独特的“内源性干细胞激活疗法”脱不开关系。现在干细胞的研究可谓是炙手可热,今年三月的时候,我国中山大

日本推出预测心梗脑梗风险网络服务

日本国立癌症研究中心等机构日前发布了一种预测中老年人心肌梗塞和脑梗塞发病风险的方法,只要在网站上输入血压、胆固醇等信息,系统就会自动计算出心肌梗塞和脑梗塞的发病风险。 这一方法实际上是以一项大型长期健康调查数据为基础的数学模型。国立癌症研究中心和藤田保健卫生大学的研究小组,对1.5万名40岁至69岁的日本人进行了平均长达16年的追踪调查,调查开始时这些人都没有心血管疾病。 研究小组跟踪记录了后来患

Nat Commun:科学家们找到新的治疗癌症的方法

(图片摘自www.sciencealert.com) 科学家们发现一种能够杀死癌细胞的新方法,即利用机体自身的细胞清除功能。来自澳大利亚研究者们通过激活细胞内部一种叫做"BAK"的蛋白质,从而促使癌细胞死亡。 "我们发现了一种全新的激活Bak蛋白的方式,这十分令人兴奋",来自Walter and Eliza Hall医学研究所的研究者之一Ruth Kluck说道。 Bak是我们体内正常

吸食大麻可致基因突变,甚至可遗传后代导致严重疾病

来自西澳大学的一项新的研究表明,吸食大麻会改变DNA,导致基因突变,从而可增加机体及其后代发生严重疾病的风险,其研究成果已在线发表于Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis。大麻是美国最常用的违禁药物,尽管其医疗或娱乐性使用合法化的地区正逐渐增加。据国家药物滥用研究所(NIDA)的数据显示,在过去的一

Baidu
map
Baidu
map
Baidu
map